Newsroom

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and du...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced new two-year follow up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor response...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with pembrolizumab for first-line (1L) treatment of recurrent/metastatic PD-L1+ head and neck squamous cell carcinoma (r/m HNSCC). In the 1L combination arm, treatment with...

MEMPHIS, Tenn.--(BUSINESS WIRE)--FedEx Corp. (NYSE: FDX) today announced the appointment of Jamere Jackson as chief financial officer, effective Nov. 30. He succeeds Claude Russ, who has served as interim CFO since June 1. Jackson brings extensive experience leading the finance function at several public companies. Most recently, he led both Finance and Store Development at AutoZone, where he has served as chief financial officer beginning in January 2021. His background combines disciplined fi...

BENTONVILLE, Ark.--(BUSINESS WIRE)--The holidays should be about making memories, not making compromises. But with budgets stretched, busy schedules and growing shopping lists, customers are looking for ways to make the season special without added stress. Walmart is making it easier with three major holiday shopping events from November 12 through December 2, bringing savings on gifts, seasonal favorites and everyday essentials – plus a new holiday marketing campaign. Walmart research shows th...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the presentation of additional clinical data for varegacestat, its investigational, oral, once-daily gamma secretase inhibitor, at the 2026 European Society for Medical Oncology (ESMO) Congress. The data were featured in four presentations, including a rapid oral presentation on patient-repo...

DALLAS--(BUSINESS WIRE)--Braemar Hotels & Resorts Inc. (NYSE: BHR) (“Braemar” or the “Company”) today announced that its Board of Directors (the “Board”) intends to nominate eight highly qualified, seasoned leaders for election at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The slate of eight director candidates includes seven new, highly qualified and independent director nominees: Craig A. Barbarosh was Senior Managing Director of CommonWealth Partners, an $8...

LOS ALTOS, Calif.--(BUSINESS WIRE)--Bidgely congratulates partner Pacific Power for receiving the 2026 Association of Edison Illuminating Companies (AEIC) Achievement Award. The recognition honors the utility’s strategic use of artificial intelligence (AI) and data analytics to identify, reach and protect vulnerable customers across Oregon and California. Pacific Power leveraged Bidgely’s UtilityAITM-powered Analytics Workbench (AWB) to uncover 37,000 hidden, yet eligible, households for enroll...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the first patient has been dosed in RESOLVE, its global Phase 2b/3 clinical trial of zelicapavir in adults at high risk of severe outcomes from RSV infection. Topline data from the Phase 2b portion of the study are expected in 2027. “We are excited to advance our zeli...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...